0001419554 false 0001419554 2023-06-28 2023-06-28 0001419554 BBLG:CommonStock0.001ParValuePerShareMember 2023-06-28 2023-06-28 0001419554 BBLG:WarrantsToPurchaseCommonStock0.001ParValuePerShareMember 2023-06-28 2023-06-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 28, 2023

 

BONE BIOLOGICS CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware   001-40899   42-1743430

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

2 Burlington Woods Drive, Ste. 100

Burlington, MA

  01803
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (781) 552-4452

 

Securities registered pursuant to section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, $0.001 par value per share   BBLG   The Nasdaq Stock Market LLC
         
Warrants to Purchase Common stock, $0.001 par value per share   BBLGW   The Nasdaq Stock Market LLC

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01 Other Events.

 

On June 28, 2023, Bone Biologics Corporation (the “Company”) received a letter (the “Letter”) from the Hearings Advisor in the Nasdaq Office of General Counsel confirming the decision of The Nasdaq Stock Market LLC’s (“Nasdaq”) Hearings Panel (the “Panel”), that the Company currently demonstrates compliance with the requirements for continued listing on The Nasdaq Capital Market for the minimum bid price, as outlined in Listing Rule 5550(a)(2).

 

Pursuant to the Letter, the Company will be subject to a “Panel Monitor,” as defined by Nasdaq Listing Rule 5815(d)(4)(A), through June 27, 2024. In the event the Company fails to satisfy a continued listing requirement during the one year monitoring period, the Company will not be provided with the opportunity to present a compliance plan to Nasdaq’s Listing Qualifications Department (the “Department”) and the Department will not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor will the Company be afforded an applicable cure or compliance period pursuant to Rule 5810(c)(3), which process might otherwise be available under the Nasdaq Listing Rules but would instead have an opportunity to request an appeal of the determination pursuant to Listing Rule 5815(d)(4)(C). The Company’s securities may at that time be delisted from Nasdaq.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 5, 2023 BONE BIOLOGICS CORPORATION
     
  By: /s/ JEFFREY FRELICK
    Jeffrey Frelick, Chief Executive Officer

 

 

 

v3.23.2
Cover
Jun. 28, 2023
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 28, 2023
Entity File Number 001-40899
Entity Registrant Name BONE BIOLOGICS CORPORATION
Entity Central Index Key 0001419554
Entity Tax Identification Number 42-1743430
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2 Burlington Woods Drive
Entity Address, Address Line Two Ste. 100
Entity Address, City or Town Burlington
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01803
City Area Code (781)
Local Phone Number 552-4452
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common stock, $0.001 par value per share  
Title of 12(b) Security Common stock, $0.001 par value per share
Trading Symbol BBLG
Security Exchange Name NASDAQ
Warrants to Purchase Common stock, $0.001 par value per share  
Title of 12(b) Security Warrants to Purchase Common stock, $0.001 par value per share
Trading Symbol BBLGW
Security Exchange Name NASDAQ

Bone Biologics (NASDAQ:BBLG)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Bone Biologics Charts.
Bone Biologics (NASDAQ:BBLG)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Bone Biologics Charts.